NCT01697319
MPS IVA, Morquio A Syndrome, Mucopolysaccharidosis IVA
The below information is taken directly from public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc. and has not been edited.
The primary objective of this study is to evaluate the effect of 2.0 mg/kg/week BMN 110 in a patient population that has limited ambulation, in a period of up to 144 weeks.
All
From 5 Years
No
BMN 110
Phase 2
Interventional
16
2012-08
2016-01-12
Oakland, California, United States
Chicago, Illinois, United States
Hamburg, , Germany
Mainz, , Germany
Birmingham, , United Kingdom
Manchester, , United Kingdom
Salford, , United Kingdom
By completing this form and clicking the send button, you understand and hereby consent to storage of your personal information, including within the United States and Europe, which will be accessible by BioMarin for purposes such as responding to your request, quality control, fulfilling compliance obligations, and assisting with products, services, or clinical trials. Depending on where you live, you may have the right to request access to, removal, or correction of your personal information held by BioMarin. You may submit your request via the contact information and/or webform located within the full BioMarin Privacy Policy.
*required fields
"*" indicates required fields